Hi Gareth, BTG has 3 major trials.
They are all late 2018/2019.
As for experience, well one of the trials has 117 centres for under 400 pts and has been recruiting for over 5 years. If every centre did 1 pt per year then they would have finished recruitment by now. All 3 appear to be very slow with recruitment - -as we know from SRX trying to get these trials to completion really is a trial - excuse the pun.
Looks as if it will be a repeat of the SARAH trial, with many centres having minimal experience of the procedure. Both SRX and BTG need to make the procedure more of a cookie cutter method, if they are to break into the big league.
The dose level on the recent SRX trails was pretty low and it will be interesting to see the dosage analysis that has been promised. No doubt we are awaiting a publication, sooner or later. Along with Ricky and the RHS data.
Anyway, the SP was been encouraging over the past few days with good volume. So maybe we will get some good news - we sorely need some!
SRX Price at posting:
$14.83 Sentiment: Buy Disclosure: Held